Bridgeway Capital Management’s Co-Diagnostics CODX Stock Holding History

Bridgeway Capital Management’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,097	Closed	-$84.5K	–	1195
2025 Q1	$84.5K	Hold	9,097	–	–	﹤0.01%	1068
2024 Q4	$205K	Hold	9,097	–	–	﹤0.01%	1004
2024 Q3	$341K	Hold	9,097	–	–	0.01%	948
2024 Q2	$341K	Hold	9,097	–	–	0.01%	942
2024 Q1	$306K	Hold	9,097	–	–	0.01%	1035
2023 Q4	$363K	Hold	9,097	–	–	0.01%	1019
2023 Q3	$289K	Hold	9,097	–	–	0.01%	1018
2023 Q2	$303K	Sell	9,097 -2,433	-21%	-$93.1K	0.01%	1042
2023 Q1	$512K	Sell	11,530 -3,083	-21%	-$247K	0.01%	882
2022 Q4	$1.1M	Hold	14,613	–	–	0.03%	714
2022 Q3	$1.41M	Buy	14,613 +1,550	+12%	+$217K	0.04%	653
2022 Q2	$2.2M	Buy	13,063 +3,670	+39%	+$558K	0.05%	506
2022 Q1	$1.74M	Buy	+9,393	New	+$1.94M	0.03%	636

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAG

Private Advisory Group Redmond, Washington $1.52B AUM 41.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgeway Capital Management's CODX Position: Q2 2025 in Review

Bridgeway Capital Management sold out of Co-Diagnostics (CODX) in Q2 2025, closing a stake of 9,097 shares — an estimated $84.5K sold.

Bridgeway Capital Management first reported a position in CODX in Q1 2022 and held it in 13 quarters. The position peaked at $2.2M in Q2 2022. 35 funds tracked by Wall St. Rank hold CODX as of Q2 2025.

Bridgeway Capital Management reported no remaining Co-Diagnostics position as of Q2 2025 after selling out during the quarter.
Bridgeway Capital Management sold 9,097 Co-Diagnostics shares in Q2 2025, an estimated $84.5K.
Bridgeway Capital Management first reported a position in Co-Diagnostics in Q1 2022 and held it in 13 quarters.
Bridgeway Capital Management's Co-Diagnostics position peaked at $2.2M in Q2 2022.
35 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2025.

Based on Bridgeway Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.